TY - JOUR
T1 - The role of PCSK9 in intestinal lipoprotein metabolism
T2 - Synergism of statin and ezetimibe
AU - Fazio, Sergio
N1 - Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.
AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.
KW - Ezetimibe
KW - LDL receptor
UR - http://www.scopus.com/inward/record.url?scp=84924943883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924943883&partnerID=8YFLogxK
U2 - 10.1016/S1567-5688(15)50006-8
DO - 10.1016/S1567-5688(15)50006-8
M3 - Article
C2 - 25659873
AN - SCOPUS:84924943883
SN - 1567-5688
VL - 17
SP - 23
EP - 26
JO - Atherosclerosis Supplements
JF - Atherosclerosis Supplements
ER -